News Information
MediaTek Chairman Wu Xiukun: Inheriting and Innovating Traditional Chinese Medicine to Support a Healthy China
Release time:
2021-03-15
Health is an eternal theme for humanity. The new concept of "Healthy China" is gradually entering the public's view. "Without national health, there can be no comprehensive well-off society!" Traditional Chinese medicine (TCM) is a medical science that has gradually formed and continuously developed over thousands of years of production and life practices of the Chinese nation. It has a unique view of life, health, disease, and prevention and treatment, which not only made outstanding contributions to the prosperity of the Chinese nation but also had a positive impact on the progress of world civilization. However, today, the development of TCM faces the challenge of inheritance and innovation. How to effectively inherit, develop, and utilize this precious wealth left to us by our ancestors has become an unavoidable question of the times for every Chinese person.
MediTech Biopharmaceutical Co., Ltd., located in Zhuhai City, leverages the original advantages of TCM, inheriting its essence, adhering to integrity and innovation, and deeply exploring, practicing, and researching. It is committed to building a unique pure TCM anti-tumor base in the country, promoting the essence of traditional TCM anti-tumor, and focusing on the research and production of anti-tumor series drugs and their supporting health products. The company has initially formed a high-tech enterprise that integrates research and development, planting, production, sales, and tumor rehabilitation, with TCM anti-tumor as the main product and supporting special medical foods and TCM decoction pieces.
Zhuhai MediTech Biopharmaceutical Co., Ltd. is a national high-tech enterprise established in April 2015, located in the Zhuhai Bio-Industry Park, covering an area of 35,000 square meters, with a construction area of 13,000 square meters for the first phase and a fixed asset investment of 130 million yuan. It is a company that integrates research and development, production, and sales of TCM anti-tumor as the leading product, including TCM, TCM decoction pieces, TCM planting, TCM internet, and special medical foods. The core product is a new anti-liver cancer drug, Sanjie Pian, which has independent intellectual property rights and has been put into production and listed. Other anti-cancer series TCMs include Baishan Pian for lung cancer and nasopharyngeal cancer, which have obtained clinical approval; varieties for treating breast cancer, cervical cancer, gastric cancer, and intestinal cancer, etc. Currently, there are 4 invention patents, 7 utility model patents, and 4 invention patents under acceptance. The company has established modern production lines for tablets, hard capsules, and TCM pre-treatment, along with corresponding research and development and inspection facilities. The annual production capacity is 500 million tablets and 200 million capsules.
Chairman Wu Xiukun of Zhuhai MediTech Biopharmaceutical Co., Ltd. graduated from Shenyang Pharmaceutical University with a degree in pharmacy. She previously worked at the pharmacology research institute of Northeast Pharmaceutical Group, the largest listed pharmaceutical company in China, and at the leading pharmaceutical company, China National Pharmaceutical Group Shenzhen Yicheng Pharmaceutical. In 2003, she founded Shenzhen Hongchang Pharmaceutical Co., Ltd. and served as chairman. Her 30 years of experience in Shenzhen, the forefront of China's reform, has cultivated her strong innovative thinking and advanced management concepts, accumulating operational and management experience in pharmaceutical research and development, sales, and industry, laying a solid foundation for the formation of the core team of MediTech.
Chairman Wu currently serves as a member of the first committee of the Quantum Medicine Science Branch of the China Water Conservancy and Electric Power Medical Science and Technology Society, an executive member of the Special Medical Food Committee of the National Food and Drug Homologous Industry Technology Innovation Alliance, and vice president of the Heilongjiang Chamber of Commerce in Zhuhai. She has been invited as a special guest on CCTV's "Discovery Journey" and the "Huashang Lun Jian - Innovative Project (Sanjie Pian)" program (available on Baidu and Youku); she has been awarded the title of "Most Influential Figure in China's Private Economy"; she donated 6 million yuan worth of anti-liver cancer drug - Sanjie Pian to the China Population Welfare Foundation charity and received the "Charity Model" medal from the China Welfare Foundation at the Great Hall of the People in Beijing on behalf of the company; during the COVID-19 pandemic, she led the company to donate "Traditional Chinese Medicine Epidemic Prevention Sachets" to Hubei and Zhuhai, and was awarded the "Advanced Unit of Pharmaceutical Science and Technology Innovation in Zhuhai" in 2019 and "Caring Enterprise in the Fight Against COVID-19 in Zhuhai" in 2020 by the Zhuhai Pharmaceutical Association.
Chairman Wu Xiukun spoke at the 12th TCM Development Forum, National Health Conference, and China (Zhuhai-Macao) TCM International Expo from November 21 to 23, 2020: Liver cancer has always been a major challenge in modern medicine. Recently, Yale University in the United States has made new breakthroughs in this field - Professor Zheng Yongqi has confirmed over 12 years that TCM anti-tumor is not only effective but also when used in conjunction with PD1, it can make tumors completely disappear, and new tumors that are re-implanted do not grow. The combination of the two produces a vaccine-like effect. This new breakthrough provides authoritative data for all TCM anti-tumor varieties, confirming the important position of TCM in the field of cancer treatment. The anti-liver cancer TCM developed by Zhuhai MediTech Biopharmaceutical Co., Ltd. - Sanjie Pian, has obtained approval from the National Medical Products Administration and is on the market. The combination of Sanjie Pian and PD1 may also create a Chinese miracle. Of course, we have already initiated the project of combining Sanjie Pian with interventional chemotherapy, and Sanjie Pian is expected to solve the medical problem of liver cancer being difficult to cure.
The anti-liver cancer TCM - Sanjie Pian has received the high-tech product certificate from Guangdong Province, won the honorary certificate for the Excellence Award in the China Innovation and Entrepreneurship Competition (Zhuhai and Guangdong divisions), and won the gold medal for the "Invention and Entrepreneurship Award - Project Award" at the National Invention Exhibition.
Under the leadership of Chairman Wu Xiukun, Zhuhai MediTech Biopharmaceutical Co., Ltd. has built an anti-tumor base for TCM, leveraging the strong support of national policies for TCM. It has passed GMP certification, and "Sanjie Pian" has met the conditions for listing. It is the only pure TCM liver cancer specialty drug in the country, with a unique formula, precise efficacy, and patent protection, making new contributions to the development of national health, promoting the progress of national medical and health work, revitalizing the national pharmaceutical industry, and enhancing the health and well-being of the people.
Related Information
Traditional Chinese Medicine for Liver Cancer and Liver Cirrhosis - Sanjie Pian, safeguarding 447 million chronic liver disease patients.
2022Year4Month15to21The day is the28first National Cancer Prevention and Control Publicity Week
In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review by the Ministry of Science and Technology, achieving a level of technological advancement that is considered leading in the country. The research and development results have been included in the National Science and Technology Achievements Database (No. 6012021Y0389). It was publicly announced on the National Science and Technology Achievements Registration Work Platform (Guokewang) in March 2022.
WeChat Subscription
Website mobile
Links:
Zhuhai Municipal Government
Guangdong Provincial Drug Administration
National Medical Products Administration
Address: Office Building Service Hotline, 150 Gate Road, Sanzao Town, Jinwan District, Zhuhai City:+86756-6331366